First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins ... ( PHILADELPHIA March 5 /- Cellvizio...)

First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference

Date:3/5/2008

PHILADELPHIA, March 5 /PRNewswire/ -- Cellvizio Inc., a leader in in vivo cellular imaging, announced today that the first live U.S. demonstration of its Cellvizio(R) GI technology will be conducted March 10, 2008, during the Johns Hopkins University School of Medicine's Eighth Annual Gastroenterology and Hepatology Viva La Vida Conference.

Cellvizio Inc. is the U.S. subsidiary of Paris-based Mauna Kea Technologies and develops and markets Cellvizio, a fundamentally new endoscopic imaging approach which could improve patient care by eliminating the need for unnecessary biopsies and could enhance the diagnosis of a broad range of diseases via in vivo cellular imaging.

The Cellvizio GI procedure will be performed at the Johns Hopkins Hospital in Baltimore during an endoscopy to assist with the diagnosis of Barrett's esophagus. It will be seen live via satellite by attendees of the conference, which is being held March 10-15 in San Juan, Puerto Rico. Gastroenterologists, surgeons and other healthcare professionals with an interest in gastroenterology and hepatology are participating in the program.

"Cellvizio allows physicians to view live tissue inside the body at the cellular level in real-time with a miniaturized microscope threaded through an endoscope and has the potential to benefit patients by reducing invasiveness while speeding up diagnosis," explained Sacha Loiseau, president, CEO and founder of Mauna Kea Technologies. "For example, a current diagnosis of Barrett's esophagus may require 10 to 50 biopsies to be taken and analyzed by a pathologist off line. The use of Cellvizio during this procedure could help reduce this number significantly by allowing physicians to avoid unnecessary biopsies."

Cellvizio GI is commercially available in Europe and in the United States.

About Mauna Kea Technologies:

Mauna Kea Technologies leads the growing in vivo cellular imaging market enabling physicians to visualize, diagnose
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
2. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant
3. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
4. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
5. BSPs New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study
6. First Complete Career Service for Life-Science Professionals
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Biopure Announces 2008 First Quarter Financial Results
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
11. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration

Post Your Comments:

First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins ...( PHILADELPHIA March 5 /- Cellvizio...)